Drug Profile
Vancomycin oral solution - Azurity Pharmaceuticals
Alternative Names: FIRVANQLatest Information Update: 02 Dec 2021
Price :
$50
*
At a glance
- Originator CutisPharma
- Developer Azurity Pharmaceuticals
- Class Antibacterials; Glycopeptides; Peptide antibiotics
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Clostridium difficile infections; Enterocolitis